In February 2019 the FDA announced that it has received a total of 660 medical device reports (MDRs) regarding breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), cases in the United States since 2010. This new total indicates an increase of about 246 new reports of breast implants lymphoma cancer cases in the past year. According to analysis, this total of 660 MDRs corresponds to 457 unique cases of BIA-ALCL, including nine patient deaths.
Next we move on to the latest news on breast implants lymphoma cancer cases in Canada, where this Information Update document was issued on February 12, 2019, “Health Canada will be updating its safety review of breast implants”, from which we get the following:
Health Canada will be updating its safety review of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) following an increase in reports of Canadian cases. As of January 1, 2019, Health Canada has received reports of 22 confirmed and 22 suspected Canadian cases of BIA-ALCL. In its initial safety review in 2017, Health Canada found that the rate of BIA-ALCL cases was low, with 5 confirmed Canadian cases of BIA-ALCL reported by Canadian manufacturers in the last 10 years. Increased awareness by healthcare professionals and the public about BIA-ALCL is believed to be the largest contributing factor to the increased reporting of cases of BIA-ALCL to Health Canada.
Be assured that we will continue to monitor medical and regulatory developments concerning breast implants lymphoma cancer cases as we have been doing since March 2017, when an update issued by the FDA brought new attention to this situation.[View article at original source]
Strictly Confidential, No Obligation.